Pathways of Inflammatory Activation in Alzheimer's Disease: Potential Targets for Disease Modifying Drugs
Epidemiological studies have shown a reduced risk of AD among users of anti-inflammatory drugs. Therefore, anti-inflammatory drugs have become the focus of several new treatment strategies. Small clinical trials with non-steroidal anti-inflammatory drugs (NSAIDs) such as indomethacin and diclofenac showed a trend for a disease modifying effect, while clinical trials with steroids did not show a beneficial effect. NSAIDs may not only act on COX-2 but also inhibit COX-1 activity or activate peroxisome proliferator-activated receptor gamma (PPAR. Among promising new strategies to reduce the inflammatory activation in the CNS interfering with intracellular pro-inflammatory pathways has been shown to be effective in various cell culture and animal models. Inhibitors of p38MAPK and PPAR agonists may be suitable agents to suppress inflammatory activation in AD.
Keywords: Alzheimers Disease; Astroglia; Microglia; anti-inflammatory drugs; cycloxygenase-2 (COX-2); non-steroidal anti-inflammatory drugs (NSAIDs); p38 mitogen-activated protein kinase (p38 MAPK); peroxisome proliferator-activated receptor
Document Type: Review Article
Publication date: 2002-01-01
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.